

STRUCTURE-ACTIVITY RELATIONSHIP STUDIES OF PHENYLNITROETHANE ANALOGUES

ADEBISI OLUWASEUN AJIBOYE
PHP09/10/H/1249

2013

STRUCTURE-ACTIVITY RELATIONSHIP STUDIES OF PHENYLNITROETHANE ANALOGUES

ADEBISI OLUWASEUN AJIBOYE

B.Sc. Chemistry (Bowen)

A THESIS SUBMITTED TO THE DEPARTMENT OF
PHARMACEUTICAL CHEMISTRY, FACULTY OF PHARMACY, OBAFEMI
AWOLOWO UNIVERSITY, ILE-IFE, NIGERIA

IN PARTIAL FULFILMENT OF THE REQUIREMENTS FOR THE
AWARD OF THE DEGREE OF MASTERS OF SCIENCE (M.Sc.) IN
PHARMACEUTICAL CHEMISTRY

2013

AUTHORISATION TO COPY

OBAFEMI AWOLOWO UNIVERSITY, ILE-IFE

HEZEKIAH OLUWASANMI LIBRARY

POSTGRADUATE THESIS**AUTHOR:** ADEBISI OLUWASEUN AJIBOYE**TITLE:** STRUCTURE-ACTIVITY RELATIONSHIP STUDIES OF
PHENYLNITROETHANE ANALOGUES**DEGREE:** M.Sc. Pharmaceutical Chemistry**YEAR:** 2013

I, Adebisi Oluwaseun Ajiboye, hereby authorise Hezekiah Oluwasanmi Library to copy my thesis in part or whole, in response to requests from individual researchers and organisations for the purpose of private study or research.

Signature and Date:

CERTIFICATION

This is to certify that Adebisi Oluwaseun AJIBOYE of the Department of Pharmaceutical Chemistry, Faculty of Pharmacy carried out this research under my supervision. This was in accordance with the requirement for the award of Master of Science (M.Sc.) degree in Pharmaceutical Chemistry, Obafemi Awolowo University, Ile-Ife, Nigeria.

Prof. T.A. Olugbade
(Supervisor)

.....
Signature and Date

Dr. J.O. Soyinka
(Head of Department)

.....
Signature and Date

DEDICATION

To the One who made the earth and ALL that is in it. I give you all the glory.

ACKNOWLEDGEMENT

I wish to place on record my immense gratitude to Prof. T.A. Olugbade for his thorough supervision, fatherly love, untiring willingness in reading through the manuscript of this thesis and above all, for his intellectual guidance and moral support.

I am equally grateful to Dr (Mrs) C.A. Elusiyan and Dr. I.A. Oyemitan for their assistance towards the successful completion of my academic programme (M.Sc) in the University. In the same vein, I am indeed grateful to Prof. A.O. Ogundaini for his assistance and the opportunity given to use facilities at the Central Science Laboratory. I will like to express my profound gratitude to all members of staff of Central Science Laboratory and Department of Pharmaceutical Chemistry who contributed to the success of this programme. I will also like to appreciate the assistance rendered by Mr Kayode Ajayi of the Department of Chemistry. God bless you all. My thanks also go to my colleagues Mr Ayorinde Adehin and Mr Morohunfolu Idebi- more ladder to climb.

My unmatched appreciation goes to my lovely parents; Rev and Mrs E.A. Ajiboye for their love, support and parental care. I extend my sincere gratitude to my darling amiable husband which his love, understanding, encouragement and support were unquantifiable and beyond comparison, without which I would not have completed the course. I say a big thank you to my siblings; Mr Adelowo Ajiboye and Mrs Oluwaseyi Olatidoye (Nee Ajiboye) for their support and prayers and the entire Abiye family, you've all been so lovely and supportive. My

acknowledgement is incomplete without appreciating my little baby, Itansanola IleriOluwatise Ajike for her cooperation and understanding. You are indeed God sent. I love you dearie.

Finally, I thank God for sparing my life to see the end of the programme and the beginning of another one.

TABLE OF CONTENTS

	Page
TITLE PAGE	i
AUTHORISATION	iii
CERTIFICATION	iv
DEDICATION	v
ACKNOWLEDGEMENT	vi
TABLE OF CONTENTS	vii
LIST OF TABLES	ix
LIST OF FIGURES... ..	x
ABBREVIATIONS	xi
ABSTRACT	xii
CHAPTER ONE INTRODUCTION	1
1.1 General Introduction	1
1.2 Description of β -phenylnitroethane	3
1.3 Some examples of synthetic β -phenylnitroethane derivatives	5
1.4 Biological Activities of β -phenylnitroethane	8
1.5 Synthesis of β -phenylnitroethane	9
1.6 Quantitative Structure-Activity Relationship (QSAR Studies)	22

1.7	Hypnosis, Convulsions and Hypothermia	36
1.8	Chromatographic techniques	40
1.9	Problem statement	42
1.10	Specific objectives of present study	43
CHAPTER TWO EXPERIMENTALS AND RESULTS							44
2.1	General experimental details	44
2.2	Protection of the Phenolic Group of Benzaldehyde Derivatives by Benzylation						45
2.3	Syntheses of β -arylnitroalcohols	46
2.4	Syntheses of β -arylnitroalkanes	49
2.5	Isolation of β -phenylnitroethane from the essential oil of <i>D. tripetala</i> using VLC						50
2.6	Lipophilicity of nitroalcohols and nitroethanes	51
2.7	Pharmacological Studies	54
CHAPTER THREE DISCUSSION							62
3.1	Benzylation of phenolic benzaldehyde derivatives	62
3.2	Synthesis of β -arylnitroethanol	69
3.3	Synthesis of β -arylnitroethanes	77
3.4	Isolation of β -phenylnitroethane from the essential oil of <i>D. tripetala</i>						82
3.5	Pharmacological studies	82
3.6	Correlation between lipophilicity and neuropharmacological activities of nitroalcohols and nitroethanes	86
CHAPTER FOUR CONCLUSION							93
REFERENCES							94



APPENDIX	104
----------	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----

OBAFEMI AWOLOWO UNIVERSITY

LIST OF TABLES

TABLE	PAGE
1. Nitroalcohols and their corresponding substituted phenylnitroethane derivatives	6
2. Diversity of promoters, catalysts and conditions for simple nitro-aldol reactions...	14
3. Preparation of β -nitroalcohol by the Henry reaction	16
4. Representative parameters of aromatic substituents	31
5. Log P of nitroalcohols and nitroethanes	52
6. Effects of nitroalcohols and nitroethanes on ketamine-induced hypnosis in mice	56
7. Effects of nitroalcohols and nitroethanes on variation in rectal temperature in mice	58
8. Anticonvulsant effects of nitroalcohols and nitroethanes on PTZ-induced convulsion model in mice	60
9. Physico-chemical data of benzyloxybenzaldehyde derivatives	66
10. ^1H NMR spectra data of benzyloxybenzaldehyde derivatives	67
11. ^{13}C NMR spectra data of benzyloxybenzaldehyde derivatives	68
12. Physico-chemical data of β -arylnitroethanol derivatives	73
13. ^1H NMR (CDCl_3) spectra data of β -arylnitroethanol derivatives	75
14. ^{13}C NMR (CDCl_3) spectra data of β -arylnitroalcohol derivatives	76
15. Physico-chemical data of β -arylnitroethane derivatives	79
16. ^1H NMR (CDCl_3) spectra data of β -arylnitroethane derivatives	80
17. ^{13}C NMR (CDCl_3) spectra data of β -arylnitroethane derivative	81
18. Effects of nitroalcohols and nitroethanes on rectal temperature in mice	85



19. Log P, hypnotic and hypothermic effects of nitroalcohols and nitroethanes ... 87

OBAFEMI AWOLOWO UNIVERSITY

LIST OF FIGURES

FIGURE	PAGE
1. Graph of a linear free energy relationship	27
2. Percentage decrease in sleep latency (SL) vs log P	90
3. Percentage increase in total sleeping time (TST) vs log P	90
4. Depression in rectal temperature at 60mins vs log P	91



ABBREVIATIONS

AGC	Accelerated Gradient Chromatography
APT	Attached Proton Test
Bn	benzyl
BPNE	β -phenylnitroethane
Cbz	benzyloxycarbonyl
DBN	1,5-diazabicyclo[4.3.0]nonene-5
DBU	1,8-diazabicyclo[5.4.0]undecene-7
DMF	<i>N,N</i> -dimethylformamide
DMSO	dimethyl sulfoxide
TLC	Thin Layer Chromatography
TMG	<i>N,N,N',N'</i> Tetramethylguanidine
TFA	trifluoroacetic acid
THF	tetrahydrofuran
TMS	tetramethylsilane
NMR	Nuclear Magnetic Resonance
PTZ	Pentylene tetrazole
VLC	Vacuum Liquid Chromatography
VS spray	Vanillin-sulphuric acid spray

ABSTRACT

This study synthesized analogues of phenylnitroethane, determined their physico-chemical properties, evaluated the pharmacological potencies and investigated the correlation between their potencies and the physico-chemical parameters. This was with a view of optimizing the lead molecule - β -phenylnitroethane (BPNE) through the evaluation of synthetic analogues for the central nervous system activities.

Derivatives of BPNE were prepared from the corresponding nitroalcohols by direct deoxygenation with triethylsilane and trifluoroacetic acid. The precursor nitroalcohols were obtained employing Henry reaction using tetramethylguanidine as a base. The starting reagents were the benzaldehyde derivatives which were initially protected by benzylation where phenolic. Intermediate and final products were purified by chromatography and identified by Nuclear Magnetic Resonance spectroscopy. The final nitroethanes and the intermediate nitroalcohols were evaluated for hypnotic effect assessed by ketamine-induced hypnosis, hypothermic effect evaluated by measuring variation in rectal temperature using rectal thermometer and anticonvulsant effect assessed by pentylenetetrazole (PTZ) - induced convulsions. Log P values were obtained using ALOGPS 2.1 applet from Virtual computational chemistry laboratory (VCCLAB). Correlation between log P and individual neuropharmacological activity was evaluated.

Seven nitroalcohols and two analogues of BPNE were obtained in addition to the lead molecule (BPNE). Four nitroalcohols [1-phenyl-2-nitroethanol (BZA), 1-(4-methoxyphenyl)-2-nitroethanol (MBP), 1-(3,4,5-trimethoxyphenyl)-2-nitroethanol (MeOB₃X) and 1-(3,4-

methylenedioxyphenyl)-2-nitroethanol (POH)] and two nitroethanes [1-(3,4-dimethoxyphenyl)-2-nitroethane (DMNE) and 1-(4-benzyloxy-3-methoxyphenyl)-2-nitroethane (BVNE)] showed significant ($P < 0.05$) decrease in sleep latency (SL) with BVNE [56.20 ± 2.47] showing superior activity to the lead molecule (BPNE) [74.60 ± 6.10]. Two nitroalcohols (MBP and POH) showed significant ($P < 0.05$) prolongation of total sleeping time (TST) with MBP [3296.80 ± 280.79] showing the best activity among the test compounds while BPNE showed a superior TST of 4584.60 ± 249.06 . None of the two test analogues of nitroethane exhibited significant ($P < 0.05$) effect on TST. Five nitroalcohols [BZA, POH, 1-(3,4-dimethoxyphenyl)-2-nitroethanol (DMP), 1-(4-benzyloxy-3-methoxyphenyl)-2-nitroethanol (BZV-ALC) and 1-(3, 4-dibenzyloxyphenyl)-2-nitroethanol (DBP)] and one nitroethane (BVNE) caused significant reduction in rectal temperature at 30 mins. Depression in the rectal temperatures for the active compounds at 60 mins post treatment were MBP (2.68 ± 0.23), DMP (2.50 ± 0.15) and DBP (2.08 ± 0.37); and that of BPNE was (1.96 ± 0.42) while that of the negative control (5% Tween 80) was 0.44 ± 0.23 . BPNE showed 100% protection on the PTZ-induced convulsions at 100 mg/kg, i.p. while none of the test compounds showed any significant anticonvulsant activity.

The study concluded that nitroalcohols with log P value less than 2.0 are likely to be hypnotically active and there is no correlation between log P, hypothermic and anticonvulsant effects. While the nitroethanes available are too few for quantitative correlation studies, the lead molecule was unique in its hypnotic and anticonvulsant activities.

INTRODUCTION

1.1

GENERAL INTRODUCTION

The rapid development and innovation in modern chemistry in the 20th century enabled scientists to synthesize new compounds and to modify naturally occurring drugs. Many drugs formerly available only from animal and plant tissues can now be produced in the chemical laboratory in a pure form. In some cases, scientists have discovered new drug compounds either by accident or by actively screening various agents for their potential pharmacologic activity (Ganesan, 2008). Physicians have relied on chemical compounds produced by animals, plants and micro-organisms; so-called natural products to treat diseases and have been the most single productive source of leads for the development of drugs. The chemistry of naturally occurring compounds has long been pursued in the search for medicines, dyes, pesticides, flavours and fragrances. However, natural products are produced in nature and through biological assays are identified as leads which become candidates for drug development (Molinari, 2009).

Synthetic chemistry plays a key role in the multidisciplinary development process of new small molecules as pharmaceuticals. Drugs are mostly organic molecules produced through chemical synthesis (Martin, 2011). They are molecules that change the physiological state of the body when taken; some act by selective toxicity principle (e.g. antibiotics), some are receptors based (e. g neuroleptics, cardiovascular agents), while some are non-receptor based (antacids). The approach to drug discovery has been to understand how disease and infection are controlled at the molecular and physiological level and to target specific entities based on this knowledge. The resulting chemical entity called the lead compound elicits the desired biological activity but may have other undesirable qualities as toxicity, poor oral absorption, poor water solubility, and


other poor pharmacokinetics properties. Thus, it is important to harness the desirable quality while the undesirable property is attenuated or eliminated. This approach is therefore called lead optimization (Olaniyi, 2005). Lead optimization is aimed at attenuating toxicity and improving the pharmacokinetic properties (absorption, distribution, metabolism and excretion) and physicochemical properties of the lead compound through modification (Olaniyi, 2005). Lead modification is achieved by first identifying the pharmacophore (the part of the lead responsible for the biological activity), homologation (increasing the carbon chain), chain branching, functional group modification, bioisosterism replacement, application of quantitative structure-activity relationship studies (Hansch, 1969).

With some classes of drugs, however, scientists have been able to discern a structure-activity relationship (i.e., a relationship between the chemical structure and the pharmacologic activity), and this information has guided the synthesis of new compounds. A structure-activity relationship (SAR) is used to determine the primary, secondary, and tertiary structure of chemicals as a means of ascertaining the relationship between the effects of different compounds on biological systems. The history of SARs is over 150 years old and goes back to the laboratory of Louis Lewin, who, in the nineteenth century, developed the early chlorinated methane derivatives chloroform, dichloromethane and carbon tetrachloride. The many derivatives of benzene (toluene, xylene, and others) also fall into this category. Once the organic chemists and medicinal chemists began to understand the impact of chemical structure on biological systems, the rudimentary basis of SARs commenced. By the 1920s, the chemistry of disinfectants, pesticides, and some drugs was based on SAR (Michael, 2002).

A classic example of an early SAR was the discovery of the benefits of acetylsalicylic acid (aspirin) and its near congeners, acetaminophen and salicylate. Another early classic

example of a SAR was the development of DDT and its analogs and congeners. Several organochlorine pesticides are members of this broad family. Modern SAR analysis is used to develop almost all drugs. Once the prototype drug is discovered and its three-dimensional characteristics determined, the scientists can then use the SAR to better understand the interaction between the drug and the affected protein or membrane (Michael, 2002).

1.2 DESCRIPTION OF β -PHENYLNITROETHANE



β -Phenylnitroethane **(1)** (1-nitro-2-phenylethane) is the second nitro compound which was isolated from nature while the first reported nitro compound from nature is the well-known antibiotic, chloramphenicol **(2)** which was isolated from a fungus, *Streptomyces venezuelae* (Horsfall, 1975).

1.2.1 Physico-chemical properties of β -phenylnitroethane

β -Phenylnitroethane is a colourless liquid of boiling point 260.5 °C at 760 mmHg. It has the molecular formula $C_8H_9NO_2$ and molecular weight of 151.1626 g/mol. The relative density of β -phenylnitroethane is 1.119 g/mL. It has a fragrant aroma with a pungent taste (Agbakwuru *et al.*, 1979).

1.2.2 Natural sources of β -phenylnitroethane



β -Phenylnitroethane was originally isolated from the essential oils of *Aniba canelilla* (Gottlieb and Magalhaes, 1959) and was identified to be responsible for the characteristic aroma of the essential oils of the plant. *A. canelilla* is a medicinal plant used in South

OBAFEMI AWOLOWO UNIVERSITY